soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial Canadian Perspectives 2025 Whiteboard on

12, e2407574

Overall, these findings provide preliminary clinical evidence for incretin-guided personalized pharmacotherapy that may improve treatment outcomes in obesity management

Bellwether trials are scheduled for late 2026 and early 2027

This shows up as harder-to-build muscle, increased body fat (especially midsection), slower recovery, lower energy, reduced bone density, and weaker immune function

The associated texting chain included in the complaint is truly something: This is where Matthew Gallagher enters the record

Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still be Effective in the Treatment of Rheumatoid Arthritis